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To the editor 
Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized 
by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas.1,2 
European recommendations are mainly based on expert opinion 3. Drug treatments are heterogenous 
(e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres.3 The most severe 
disease forms or those failing to respond to conventional drugs may be associated with worsened 
functional prognosis. Anti-tumor necrosis factor  (anti-TNF) drugs have been prescribed in these 
cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the 
efficacy of adalimumab (ADA),4-6 and two others did not detect any difference between infliximab 
(IFX) or etanercept (ETA) and placebo.7,8 Finally, data from the literature and reported experiences do 
not conclude on the efficacy of anti-TNF drugs for HS.  
The aim of this study was to assess the efficacy of anti-TNF drugs in patients with HS seen in 
routine care.  
We conducted a national retrospective cohort. Patients who presented HS and who received at 
least one anti-TNF drug during the evolution of the disease were eligible. We contacted 25 centres, 
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including mainly teaching hospitals (n=22) but also general hospitals (n=3). Eleven had eligible 
patients, 7 had no eligible patients and the 7 other centres did not respond to our requests.  
For each centre with eligible patients, patients were selected by a cross-examination of data from 
January 1, 2000 to December 31, 2013 in 3 databases (the dermatology department databases, the 
national database in France PMSI, Programme de Médicalisation des Systèmes d’Information and the 
hospital pharmacy databases). Duplicates were excluded.  
A standardized form was used to record sociodemographic characteristics. Associated 
inflammatory diseases were also recorded, as was personal history of HS. Anatomic zones involved at 
least once in the history of the patient were classified as breast and armpit, follicular and gluteal 
involvement.9 Disease severity was evaluated at the time of clinical examination by the Hurley grade. 
Details of the anti-TNF therapy recorded included the molecule, dosage, treatment duration, and 
adverse effects.   
Patients were classified into 3 groups of response after first-line anti-TNF treatment: (1) 
complete response (resolution of all skin lesions or at least 90% improvement), (2) partial response (at 
least 50% improvement), and (3) no response. Event-free survival was measured from the date of the 
beginning of anti-TNF treatment to the date of the first relapse or lost to follow-up. The factors that 
could influence progression-free survival times were tested with Cox’s proportional hazards model.  
Among 18 centres, we identified 67 patients with HS (37 [55.2%] women; median age 38.0 
years (range 10.9–71.8 years) who received an anti-TNF drug during this 13-year period. 
Characteristics of the study population are in Table 1. The most frequent anti-TNF drug prescribed as 
first-line treatment was IFX, 5 mg/kg (n=57/66, 86.4%), then ADA, 40 mg every 2 weeks (n=7/66, 
10.6%) and ETA, 50 mg twice a week (n=2/66, 3.0 %). The median follow-up was 6.8 months 
[interquartile range (IQR) 3.6–19.1]. Eight cases (11.9%) achieved complete response, 31 (46.2%) 
partial response and 25 (37.3%) no response, 3 (4.6%) had just been treated by anti- TNF drugs and 
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monitoring data were not available. The median follow-up for the 3 groups was 22.8 [10.4–44.2], 13.2 
[4.7–22.9] and 4.6 [1.4–7.9] months, respectively. Twelve patients (17.9%) received 2 anti- TNF 
drugs and 5 (7.4%), 3. 
Factors associated with a complete or at least a partial response to first line anti-TNF therapy 
in univariate and multivariate analysis are summarized Table 2. On multivariate analysis, complete 
response to first line anti-TNF therapy was independently associated with currently smoking (hazard 
ratio [HR] 8.4, 95% confidence interval 1.3–56.0; p=0.03) and associated inflammatory bowel or 
arthritis diseases (HR 6.8, 1.2–40.0; p=0.03). Only one patient with an inflammatory arthritis disease 
who achieved complete response had received another immunosuppressive treatment (methotrexate). 
Partial response to first line anti-TNF therapy was associated with only ADA treatment (HR 6.6, 2.2–
19.7), p=0.001). In total, 5/7 patients (71.4%) receiving ADA achieved a partial response and none 
receiving ADA had a complete response. Four patients had to stop anti-TNF treatment because of 
severe side effects (1 case each of hepatitis, lupus, repeated urinary tract infection, and pulmonary 
embolism).  
Our results suggest modest and inconsistent efficacy of anti-TNF therapy for moderate to 
severe HS. Complete and persistent clinical responses were rarely obtained (11.9%) and partial 
response was achieved in 46.2% of patients. These results are consistent with a retrospective Spanish 
cohort study of 19 patients.10 Anti-TNF therapy could be efficient in this subset of patients presenting 
an associated inflammatory disorder.  
Currently smoking was an independent factor associated with a complete response to anti-
TNF therapy. These results are contrary to data provided by registers dealing with inflammatory 
arthritis.11 However, previous reports had suggested that smokers, particularly those who smoked 
before the HS, had a less severe form of HS than never-smokers.12 In addition, current smoking is a 
protective factor in other inflammatory diseases such as ulcerative colitis.13 Larger studies are needed 
to better determine the protective effect of tobacco use in patients with HS.  
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Finally, partial response to anti-TNF therapy was about 7 times higher for patients who 
received ADA as compared with ETA or IFX. This result highlights a possible class effect of ADA 
and agrees with results of other RCTs and the recent approval of ADA (40 mg weekly after initial 
doses of 160 mg at week 0 and 80 mg at week 2) as a possible treatment for patients with active 
moderate to severe HS by the European Medicines Agency (EMA).4-6,14 Higher dosages of ADA as 
mentioned above might be associated with higher response rates as compared with a standard dosage 
(40 mg every 2 weeks).5 All patients of our cohort received the standard dosage which could have 
undermined the overall response rate. 
.  
To conclude, anti-TNF therapy in patients with moderate to severe HS seems more efficient 
in a subset of patients with associated arthritis or inflammatory bowel disorder. Complete and 
persistent clinical response, with anti-TNF drugs used as a single agent, was rarely obtained. ADA 
seems to be more efficient than IFX and ETA. Other therapeutic strategies, such as anti-TNF drugs 
especially higher dosages of ADA used before surgery or low dose methotrexate in combination, have 
yet to be assessed.  
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Table 1. Initial characteristics of patients with hidradenitis suppurativa (HS) who received an anti-
tumor necrosis factor α (anti-TNF) drug (n=67) 
Characteristics (n=missing data) N (%) 
Women 37 (55.2)
Age, years, median (range) 38.0 (10.9–71.8) 
Smoking status (n=5) 
  Non-smoker 
 Current smoker 
  Ex-smoker 
19 (30.7) 
34 (54.8) 
9 (14.5) 
Body mass index, kg/m2, median (range) 
  >25 
  >30 
28.0 (16.7–53) 
48 (71.6) 
29 (43.4) 
History of severe acne 13 (19.4) 
HS phenotype * 
 Classical 32 (47.8) 
 Follicular 14 (20.9) 
 Gluteal 21 (31.3) 
Highest Hurley grade (n=5) 
  II 
  III 
16 (25.8) 
46 (74.2) 
Associated inflammatory disorder 
  Inflammatory bowel disease 
  Inflammatory arthritis 
  Inflammatory bowel diseases or arthritis  
2 (3) 
11 (16.4) 
12 (17.9) 
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 Neutrophilic skin disease 8 (12) 
Fist line anti-TNF treatment (n=1) 
 Adalumimab  
  Infliximab 
  Etanercept 
7 (10.6) 
57 (86.4) 
2 (3) 
Second line anti- TNF treatment 
 Adalumimab  
  Infliximab 
  Etanercept 
12 (17.9) 
9/12 (52.9) 
5/12 (29.4) 
3/12 (17.7) 
Third line anti- TNF treatment 
 Adalumimab  
  Infliximab 
  Etanercept 
5 (13.4) 
1/5 (20) 
1/5 (20) 
3/5 (60) 
Data are no. (%) unless indicated 
*Canoui-Poitrine et al, J Invest Dermatol 2013; 133:1506-11
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